Trial Profile
A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms ZACTHYF
- Sponsors Sanofi Genzyme
- 03 Oct 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 20 Oct 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2022.
- 05 Feb 2021 Planned End Date changed from 31 Dec 2020 to 1 Dec 2021.